| 1 Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia:rationale and important changes[J]. Blood, 2009, 114:937-951.2 Landolfi R, Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms[J]. Haematologica, 2011, 96:183-186.3 Colombi M, Radaelli F, Zocchi L, et al. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients[J]. Cancer, 1991, 67:2926-2930.4 Jensen MK, de Nully Brown P, Nielsen OJ, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area[J]. Eur J Haematol, 2000, 65:132-139.5 Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia:prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia[J]. Arch Intern Med, 2005, 165:2651-2658.6 Reisner SA, Rinkevich D, Markiewicz W, et al. Cardiac involvement in patients with myeloproliferative disorders[J]. Am J Med, 1992, 93:498-504.7 Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia:a study of the predictive factors in a series of 148 patients[J]. Leukemia, 1999, 13:150-154.8 Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera:long-term results in 163 patients[J]. Haematologica, 2000, 85:1011-1018.9 Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera[J]. J Clin Oncol, 2005, 23:2224-2232.10 Pardanani A, Lasho TL, Hussein K, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm:assessment of value in a series of 664 consecutive patients[J]. Mayo Clin Proc, 2008, 83:457-459.11 Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera[J]. Blood, 2007, 109:2446-2452.12 De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia:incidence, risk factors, and effect of treatments[J]. Haematologica, 2008, 93:372-380.13 Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia:an international study of 891 patients[J]. Blood, 2011, 117:5857-5859.14 Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis:incidence and risk factors[J]. Blood, 2010, 115:778-782.15 Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia:interaction with treatment, standard risk factors, and JAK2 mutation status[J]. Blood, 2007, 109:2310-2313.16 Vannucchi AM. JAK2 mutation and thrombosis in the myeloproliferative neoplasms[J]. Curr Hematol Malig Rep, 2010, 5:22-28.17 Tefferi A. The granulocyte connection in MPD-associated thrombosis[J]. Blood, 2007, 109:2270-2271.18 Zerjavic K, Zagradisnik B, Stangler S, et al. Is the JAK2V617F mutation a hallmark for different forms of thrombosis?[J]. Acta Haematol, 2010, 124:49-56.19 McCarthy N, McCarron SL, Langabeer SE, et al. Prevalence of the JAK2V617F and MPL mutations in stroke, abdominal and peripheral venous thrombosis[J]. Acta Haematol, 2010, 124:160-161.20 Ziakas PD. Effect of JAK2V617F on thrombotic risk in patients with essential thrombocythemia:measuring the uncertain[J]. Haematologica, 2008, 93:1412-1414.21 Kurosawa H, Okuya M, Matsushita T, et al. JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis[J]. J Pediatr Hematol Oncol, 2009, 31:678-680.22 Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:a critical reappraisal[J]. Leukemia, 2008, 22:1299-1307.23 De Stefano V, Za T, Rossi E, et al. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2V617F mutation[J]. Ann Hematol, 2010, 89:141-146.24 Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden[J]. Leukemia, 2007, 21:1952-1959.25 Xavier SG, Gadelha T, Rezende SM, et al. JAK2V617F mutation in patients with thrombosis:to screen or not to screen?[J]. Int J Lab Hem, 2011, 33:117-124.26 Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia:relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules[J]. Exp Hematol, 2007, 35:702-711.27 Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia[J]. Blood, 2010, 116:1205-1210.28 Barbui T. How to manage thrombosis in myeloproliferative neoplasms[J]. Curr Opin Oncol, 2011, 23:654-658.29 Bogousslavsky J, Van Melle G, Regli F, et al. The Lausanne Stroke Registry:Analysis of 1,000 consecutive patients with first stroke[J]. Stroke, 1988, 19:1083-1092.30 Adams HP, Butler MJ, Biller J, et al. Nonhemorrhagic cerebral infarction in young adults[J]. Arch Neurol, 1986, 43:793-796. |
